APOC3, coronary disease, and complexities of mendelian randomization

Jonathan C. Cohen; Stefan Stender; Helen H. Hobbs

doi:10.1016/j.cmet.2014.08.007

APOC3, coronary disease, and complexities of mendelian randomization

Jonathan C. Cohen, Stefan Stender, Helen H. Hobbs

Research output: Contribution to journal › Short survey › peer-review

34 Scopus citations

Abstract

Two new studies report that triglyceride (TG)-lowering mutations in APOC3 reduce coronary heart disease (CHD) (Crosby et al., 2014; Jørgensen et al., 2014). Here, we explore limitations of using Mendelian randomization to evaluate CHD risk, including potential confounding by the widespread use of statin therapy.

Original language	English (US)
Pages (from-to)	387-389
Number of pages	3
Journal	Cell Metabolism
Volume	20
Issue number	3
DOIs	https://doi.org/10.1016/j.cmet.2014.08.007
State	Published - Sep 2 2014

ASJC Scopus subject areas

Physiology
Molecular Biology
Cell Biology

Access to Document

10.1016/j.cmet.2014.08.007

Cite this

@article{7b8e6f8805eb4fbe93135f0414cba593,

title = "APOC3, coronary disease, and complexities of mendelian randomization",

abstract = "Two new studies report that triglyceride (TG)-lowering mutations in APOC3 reduce coronary heart disease (CHD) (Crosby et al., 2014; J{\o}rgensen et al., 2014). Here, we explore limitations of using Mendelian randomization to evaluate CHD risk, including potential confounding by the widespread use of statin therapy.",

author = "Cohen, {Jonathan C.} and Stefan Stender and Hobbs, {Helen H.}",

year = "2014",

month = sep,

day = "2",

doi = "10.1016/j.cmet.2014.08.007",

language = "English (US)",

volume = "20",

pages = "387--389",

journal = "Cell Metabolism",

issn = "1550-4131",

publisher = "Cell Press",

number = "3",

}

TY - JOUR

T1 - APOC3, coronary disease, and complexities of mendelian randomization

AU - Cohen, Jonathan C.

AU - Stender, Stefan

AU - Hobbs, Helen H.

PY - 2014/9/2

Y1 - 2014/9/2

N2 - Two new studies report that triglyceride (TG)-lowering mutations in APOC3 reduce coronary heart disease (CHD) (Crosby et al., 2014; Jørgensen et al., 2014). Here, we explore limitations of using Mendelian randomization to evaluate CHD risk, including potential confounding by the widespread use of statin therapy.

AB - Two new studies report that triglyceride (TG)-lowering mutations in APOC3 reduce coronary heart disease (CHD) (Crosby et al., 2014; Jørgensen et al., 2014). Here, we explore limitations of using Mendelian randomization to evaluate CHD risk, including potential confounding by the widespread use of statin therapy.

UR - http://www.scopus.com/inward/record.url?scp=84913596368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84913596368&partnerID=8YFLogxK

U2 - 10.1016/j.cmet.2014.08.007

DO - 10.1016/j.cmet.2014.08.007

M3 - Short survey

C2 - 25185943

AN - SCOPUS:84913596368

SN - 1550-4131

VL - 20

SP - 387

EP - 389

JO - Cell Metabolism

JF - Cell Metabolism

IS - 3

ER -

APOC3, coronary disease, and complexities of mendelian randomization

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this